Resources

Past Presentation

Induction with Buprenorphine for Pregnant & Parenting Patients with SUD | December 1st 2022

Type: Past Presentation  

Audience: Clinical  

Program: Substance Use Disorder ECHO Program  

Keywords: #advocacy  #buprenorphine  #pregnancy  #SUD  #SUD treatment  

In this presentation, Dr. Mishka Terplan, discusses professional recommendations on buprenorphine (and methadone) as a safe and effective treatment option during pregnancy and for parenting individuals. He presents maternal benefits of MOUD which include 70% reduction in overdose related deaths, decrease in risk of HIV, HBV, HCV acquisition/transmission, increased engagement in prenatal care and recovery treatment, and treatment is a platform for delivery of other services. Fetal benefits noted include reduces fluctuations in maternal opioid levels; reducing fetal stress, decrease in intrauterine fetal demise, decrease in intrauterine growth restriction, and decrease in preterm delivery. 

 

Recording:

Presented by:

Mishka Terplan, MD, MPH, FACOG, DFASAM

Dr. Mishka Terplan is board certified in both obstetrics and gynecology and in addiction medicine. His primary clinical, research and advocacy interests lie along the intersections of reproductive and behavioral health. Dr. Terplan is nationally recognized as an expert in the care of pregnant and parenting people with substance use disorder. He has been central to guidance document development at the American Congress of Obstetrician Gynecologists (ACOG), the American Society of Addiction Medicine (ASAM) and the Substance Abuse and Mental Health Services Administration (SAMHSA) and has participated in expert panels at Center for Disease Control, Office of the National Drug Control Policy, Office of Women’s Health, US Food and Drug Administration and the National Institutes of Health primarily on issues related to gender and addiction. Dr. Terplan has active grant funding and has published over 100 peer-reviewed articles with emphasis on addiction medicine, drug use in pregnancy, health disparities, stigma, and access to treatment.

Dr. Terplan is the Associate Medical Director at Friends Research Institute, the Addiction Medicine Consultant for Virginia Medicaid and adjunct faculty at the University of California, San Francisco where he is a Substance Use Warmline clinician for its Clinical Consultation Center.

Resources Provided:

Date added: December 1, 2022